ArticleTranslational psychiatry2017
Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study.
Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals.Molecular psychiatry · 2020Trial
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.The American journal of psychiatry · 2018Trial
- Naltrexone/Bupropion/Mirtazapine Triple Therapy for Treatment-Resistant Methamphetamine Use Disorder: A Case Series.Cureus · 2026Article
- Role of the mesolimbic dopamine pathway in the antidepressant effects of ketamine.Neuropharmacology · 2023Review
- Current and Emerging Treatments for Methamphetamine Use Disorder.Current neuropharmacology · 2021Review
- Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.Journal of systems and integrative neuroscience · 2020Article
- The role of the opioid system in decision making and cognitive control: A review.Cognitive, affective & behavioral neuroscience · 2019Review
- Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.EC psychology and psychiatry · 2018Article
- Serotonin concentration enhancers at clinically relevant doses reduce [Translational psychiatry · 2018Article
- Verification of a genetic locus for methamphetamine intake and the impact of morphine.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The opioid antagonist naltrexone has been shown to attenuate the subjective effects of amphetamine. However, the mechanisms behind this modulatory effect are currently unknown. We hypothesized that naltrexone would diminish the striatal dopamine release induced by amphetamine, which is considered an important mechanism behind many of its stimulant properties. We used positron emission tomography and the dopamine D2-receptor radioligand [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.